Endocrine treatment options for advanced breast cancer--the role of fulvestrant.

Robertson, J F R; Come, S E; Jones, S E; Beex, L; Kaufmann, M; Makris, A; Nortier, J W R; Possinger, K; Rutqvist, L-E

Robertson, J F R; Come, S E; Jones, S E; Beex, L; Kaufmann, M; Makris, A; Nortier, J W R; Possinger, K; Rutqvist, L-E.

Affiliation

Robertson JF; Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK. john.robertson@nottingham.ac.uk

Eur J Cancer ; 41(3): 346-56, 2005 Feb.

Article in En | MEDLINE | ID: mdl-15691633

Subject(s)

Antineoplastic Agents, Hormonal/therapeutic use; Breast Neoplasms/drug therapy; Estradiol/analogs & derivatives; Estradiol/therapeutic use; Estrogen Antagonists/therapeutic use; Anastrozole; Androstadienes/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Female; Fulvestrant; Gefitinib; Humans; Nitriles/administration & dosage; Postmenopause; Quinazolines/administration & dosage; Tamoxifen/therapeutic use; Treatment Outcome; Triazoles/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Agents, Hormonal / Estradiol / Estrogen Antagonists Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2005 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links